Treating and Preventing Adolescent Mental Health Disorders: Treating and Preventing Adolescent Mental Health Disorders

Home > Table of Contents

Book Title: Treating and Preventing Adolescent Mental Health Disorders > pp. [805]

UNDEFINED: AUTHORS

Treating and Preventing Adolescent Mental Health Disorders

Print ISBN 9780195173642, 2005
pp. [805]

inadequacy of resources , 589 , 593–94 , 610 , 614

minor consent for , 566–67

Mental Health Parity Act , 555

Mental health professionals

physician collaboration with , 589

referral to

primary care physician practices , 586 , 587 t, 588 , 591–92 , 591 t, 593

school practices , 598 , 606 , 607–08 , 607 t

Mental health services

access to

cultural barriers , 552–53

in schools , 598–599 , 604–5 , 604 t, 605 t

survey findings , 589 , 593–94 , 610

system barriers , 551–52

delivery systems . See Service delivery systems, mental health

evidence-based . See Evidence-based mental health services

in primary care settings . See under Primary care setting

school-based . See under Schools

settings , xxxvii–xxxviii

substance abuse–related , 565 , 570

Mescaline , 371

Mesosystem , 501

Methadone, for opioid addiction , 403 , 406

Methamphetamine dependence , 349–53 . See also Stimulant abuse

Methodological Epidemiologic Catchment Area Study , 19–20 , 21 t

Mexican Americans

access to mental health services , 553

depression in , 61

Michigan, reform initiatives on delivery of evidence-based practices , 556

Microsystem , 501

Minnesota Twelve-Step model, for substance use disorders , 393–94 , 398

Minor consent for services , 566–67

Molecular genetic studies, in schizophrenia , 106–7

Molindone, for schizophrenia , 122 t

Monitoring the Future (MTF) study , 342

Monoamine oxidase inhibitors, for major depressive disorder , 43

Mood disorders , xxv . See also Bipolar disorder; Depression

age of onset , 4–5

biology , 24–27

comorbidity

alcohol use disorders , 362

eating disorders , 272 , 273

epidemiology and definitions , 4–27

relationship to schizophrenia , 102

research agenda , 70–74

in schizophrenia , 126

seasonal , 6

suicidal behavior and , 437

trait vulnerability factor common to , 10–11

treatment , 30–54

Mood stabilizers , 296–300 , 298t–299 t. See also specific drugs, e.g., Lithium

for bipolar disorder

in adolescents , 51–52 , 52 t

in adults , 50

combination therapy , 53–54

for schizophrenia , 126

Moral competence, as outcome of positive youth development , 504

Motivational interview, in substance use disorders , 397–98

Motor deficits, in schizophrenia , 83–84 , 137–38 , 138 f, 139 f, 145 t, 146 , 147 , 148–49

Multidimensional Anxiety Scale for Children (MASC), 233

Multidimensional family therapy, for substance use disorders , 396

Multisystemic therapy, for substance use disorders , 395

Mutism, selective , 193–94

maintenance of gains , 215

treatment , 189 t, 194 , 214 t

Myelinization

brain , xxix, 86 , 87 f

in schizophrenia , 86–88 , 91

Naltrexone

for alcohol use disorders , 405

for opioid addiction , 406

Narcotic abuse . See Opioid abuse

National Alliance for Mental Illness , 547

National Annenberg Risk Survey of Youth (NARSY), 533 , 534 t

National Comorbidity Survey , 342–43

bipolar disorder , 19

depression , 7–8 , 8 f

National Household Survey on Drug Use and Health (NHSDUH), 342

National Institute of Mental Health Center for Prevention Research , 57

National Registry of Effective Practices (NREP), 555

National Youth Anti-Drug Media Campaign , 419–21

Native Americans

substance use , 345

suicide prevention programs , 464

suicide rate , 436

Nefazodone, for major depressive disorder

in adults , 43 , 47

in children and adolescents , 44–45 , 45 t

end p.805